Cargando…
A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C
Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer. Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking o...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2000
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374494/ https://www.ncbi.nlm.nih.gov/pubmed/10755406 http://dx.doi.org/10.1054/bjoc.1999.1096 |